ACRP Announces TransCelerate's Intentions to Accept its Certification
Clinical research professionals who have a current CPI or CCRC designation will be able to use that as evidence that retaking GCP training is not necessary if they are working on a trial for one of the TransCelerate companies.
The ACRP announced that TransCelerate BioPharma is accepting its affiliate’s certifications for Certified Clinical Research Coordinator (CCRC®) and Certified Physician Investigator (CPI®) as evidence of Good Clinical Practice (GCP) training.
That TransCelerate’s membership companies are accepting these certifications to eliminate redundant GCP training for each and every new study team the coordinators or investigators join is not a surprise. This initiative to create efficiencies in the clinical trials process was one of the original five targets set forth in TransCelerate’s formation. Specifically, at that time it said of Site Qualification and Training , its goal was “To build upon the creation of common criteria for mutual recognition of GCP training and common forms to collect generic information about study sites, TransCelerate will provide a common framework to streamline the process for qualifying investigator sites, and standardizing non-protocol specific forms for clinical trials. The organization will also establish criteria for training site personnel new to clinical research and trials.”
The ACRP affiliate--the Academy of Clinical Research Professionals (the Academy)--have produced more than 28,500 certificants in more than 60 countries since 1992 (including the CPI, CCRC, and Certified Clinical Research Associate [CCRA®] programs.
At posting time, TransCelerate had not yet posted its release or comments. You can read the ACRP's full release here.
FDA Grants Priority Review to Merck’s sBLA for Winrevair After Early Success in ZENITH PAH Trial
July 2nd 2025Merck’s bid to update Winrevair’s label advances with FDA priority review, backed by Phase III ZENITH data showing a 76% reduction in major morbidity and mortality events in patients with pulmonary arterial hypertension.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.
Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025
June 27th 2025At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.
